June 8, 2021
FDA approves new Alzheimer's drug
The FDA granted accelerated approval for a new Alzheimer’s drug for the first time since 2003 yesterday, finding that the drug is “reasonably likely” to provide a clinical benefit. The drug (“Aduhelm”) has faced mixed feedback from the scientific community, with an FDA advisory panel recommending against approval last year.
